The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium

Muriel Doret, Georges Mellier, Pascal Gaucherand, George Saade, Mehdi Benchaib, Jean Frutoso, Jean Charles Pasquier

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: To compare the tocolytic potency of ritodrine, nicardipine and atosiban, used alone and in dual combinations, to see whether combinations of these drugs, which act via different pathways, could improve inhibition of uterine contractility. Design: Study on myometrial contractility in vitro. Setting: Laboratory of physiology, Lyon, France. Sample: Longitudinal myometrial strips from non-labouring timed pregnant Wistar rats (18 gestational days). Methods: Strips were simultaneously exposed to EC25, EC50 or EC75 of dual combinations of either ritodrine and nicardipine, ritodrine and atosiban or nicardipine and atosiban (n = 10/group). Basal contractile activity and contractile activity after addition of each combination was measured using the 10 min integral of activity. Changes were expressed as percentage from the basal 10 min integral activity. The observed percentage inhibition of activity was compared with the expected percentage inhibition in an additive pharmacological model. When no significant difference occurred, the combination was deemed simply to have an additive tocolytic effect. When inhibition of activity was significantly greater compared with the expected percentage inhibition, the combination was deemed to have a synergistic effect. Main outcome measure: Changes in integral contractile activity in response to tocolytic combinations. Results: Ritodrine and atosiban inhibited integral activity to a greater extent than expected [e.g. using EC50: observed inhibition 88.9% (13.8%) vs expected inhibition 75%; P < 0.015]. Actual inhibition by nicardipine/ritodrine [78.55% (20.4%) vs 75%; P = n.s.] and nicardipine/atosiban [78.94% (17.8%) vs 75%; P = n.s.] was not significantly different from expected. Conclusions: A combination of ritodrine plus atosiban exhibits a synergistic inhibition for myometrial activity, thus allowing the use of lower concentrations of each drug to achieve the same effect compared with each drug used alone. Combination of nicardipine plus ritodrine and nicardipine plus atosiban achieves only an additive effect. The potential for decreasing side effects (beta-mimetics) and costs (atosiban) when using a combination in clinical practice needs to be evaluated.

Original languageEnglish (US)
Pages (from-to)731-734
Number of pages4
JournalBJOG: An International Journal of Obstetrics and Gynaecology
Volume110
Issue number8
DOIs
StatePublished - Aug 1 2003

Fingerprint

Ritodrine
Nicardipine
Myometrium
Tocolytic Agents
In Vitro Techniques
atosiban
Drug Combinations
Pharmaceutical Preparations
France
Wistar Rats
Outcome Assessment (Health Care)
Pharmacology
Costs and Cost Analysis

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium. / Doret, Muriel; Mellier, Georges; Gaucherand, Pascal; Saade, George; Benchaib, Mehdi; Frutoso, Jean; Pasquier, Jean Charles.

In: BJOG: An International Journal of Obstetrics and Gynaecology, Vol. 110, No. 8, 01.08.2003, p. 731-734.

Research output: Contribution to journalArticle

Doret, Muriel ; Mellier, Georges ; Gaucherand, Pascal ; Saade, George ; Benchaib, Mehdi ; Frutoso, Jean ; Pasquier, Jean Charles. / The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium. In: BJOG: An International Journal of Obstetrics and Gynaecology. 2003 ; Vol. 110, No. 8. pp. 731-734.
@article{69ddae0f3f284842a6570a8d223821e7,
title = "The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium",
abstract = "Objective: To compare the tocolytic potency of ritodrine, nicardipine and atosiban, used alone and in dual combinations, to see whether combinations of these drugs, which act via different pathways, could improve inhibition of uterine contractility. Design: Study on myometrial contractility in vitro. Setting: Laboratory of physiology, Lyon, France. Sample: Longitudinal myometrial strips from non-labouring timed pregnant Wistar rats (18 gestational days). Methods: Strips were simultaneously exposed to EC25, EC50 or EC75 of dual combinations of either ritodrine and nicardipine, ritodrine and atosiban or nicardipine and atosiban (n = 10/group). Basal contractile activity and contractile activity after addition of each combination was measured using the 10 min integral of activity. Changes were expressed as percentage from the basal 10 min integral activity. The observed percentage inhibition of activity was compared with the expected percentage inhibition in an additive pharmacological model. When no significant difference occurred, the combination was deemed simply to have an additive tocolytic effect. When inhibition of activity was significantly greater compared with the expected percentage inhibition, the combination was deemed to have a synergistic effect. Main outcome measure: Changes in integral contractile activity in response to tocolytic combinations. Results: Ritodrine and atosiban inhibited integral activity to a greater extent than expected [e.g. using EC50: observed inhibition 88.9{\%} (13.8{\%}) vs expected inhibition 75{\%}; P < 0.015]. Actual inhibition by nicardipine/ritodrine [78.55{\%} (20.4{\%}) vs 75{\%}; P = n.s.] and nicardipine/atosiban [78.94{\%} (17.8{\%}) vs 75{\%}; P = n.s.] was not significantly different from expected. Conclusions: A combination of ritodrine plus atosiban exhibits a synergistic inhibition for myometrial activity, thus allowing the use of lower concentrations of each drug to achieve the same effect compared with each drug used alone. Combination of nicardipine plus ritodrine and nicardipine plus atosiban achieves only an additive effect. The potential for decreasing side effects (beta-mimetics) and costs (atosiban) when using a combination in clinical practice needs to be evaluated.",
author = "Muriel Doret and Georges Mellier and Pascal Gaucherand and George Saade and Mehdi Benchaib and Jean Frutoso and Pasquier, {Jean Charles}",
year = "2003",
month = "8",
day = "1",
doi = "10.1111/j.1471-0528.2003.02443.x",
language = "English (US)",
volume = "110",
pages = "731--734",
journal = "BJOG: An International Journal of Obstetrics and Gynaecology",
issn = "1470-0328",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - The in vitro effect of dual combinations of ritodrine, nicardipine and atosiban on contractility of pregnant rat myometrium

AU - Doret, Muriel

AU - Mellier, Georges

AU - Gaucherand, Pascal

AU - Saade, George

AU - Benchaib, Mehdi

AU - Frutoso, Jean

AU - Pasquier, Jean Charles

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Objective: To compare the tocolytic potency of ritodrine, nicardipine and atosiban, used alone and in dual combinations, to see whether combinations of these drugs, which act via different pathways, could improve inhibition of uterine contractility. Design: Study on myometrial contractility in vitro. Setting: Laboratory of physiology, Lyon, France. Sample: Longitudinal myometrial strips from non-labouring timed pregnant Wistar rats (18 gestational days). Methods: Strips were simultaneously exposed to EC25, EC50 or EC75 of dual combinations of either ritodrine and nicardipine, ritodrine and atosiban or nicardipine and atosiban (n = 10/group). Basal contractile activity and contractile activity after addition of each combination was measured using the 10 min integral of activity. Changes were expressed as percentage from the basal 10 min integral activity. The observed percentage inhibition of activity was compared with the expected percentage inhibition in an additive pharmacological model. When no significant difference occurred, the combination was deemed simply to have an additive tocolytic effect. When inhibition of activity was significantly greater compared with the expected percentage inhibition, the combination was deemed to have a synergistic effect. Main outcome measure: Changes in integral contractile activity in response to tocolytic combinations. Results: Ritodrine and atosiban inhibited integral activity to a greater extent than expected [e.g. using EC50: observed inhibition 88.9% (13.8%) vs expected inhibition 75%; P < 0.015]. Actual inhibition by nicardipine/ritodrine [78.55% (20.4%) vs 75%; P = n.s.] and nicardipine/atosiban [78.94% (17.8%) vs 75%; P = n.s.] was not significantly different from expected. Conclusions: A combination of ritodrine plus atosiban exhibits a synergistic inhibition for myometrial activity, thus allowing the use of lower concentrations of each drug to achieve the same effect compared with each drug used alone. Combination of nicardipine plus ritodrine and nicardipine plus atosiban achieves only an additive effect. The potential for decreasing side effects (beta-mimetics) and costs (atosiban) when using a combination in clinical practice needs to be evaluated.

AB - Objective: To compare the tocolytic potency of ritodrine, nicardipine and atosiban, used alone and in dual combinations, to see whether combinations of these drugs, which act via different pathways, could improve inhibition of uterine contractility. Design: Study on myometrial contractility in vitro. Setting: Laboratory of physiology, Lyon, France. Sample: Longitudinal myometrial strips from non-labouring timed pregnant Wistar rats (18 gestational days). Methods: Strips were simultaneously exposed to EC25, EC50 or EC75 of dual combinations of either ritodrine and nicardipine, ritodrine and atosiban or nicardipine and atosiban (n = 10/group). Basal contractile activity and contractile activity after addition of each combination was measured using the 10 min integral of activity. Changes were expressed as percentage from the basal 10 min integral activity. The observed percentage inhibition of activity was compared with the expected percentage inhibition in an additive pharmacological model. When no significant difference occurred, the combination was deemed simply to have an additive tocolytic effect. When inhibition of activity was significantly greater compared with the expected percentage inhibition, the combination was deemed to have a synergistic effect. Main outcome measure: Changes in integral contractile activity in response to tocolytic combinations. Results: Ritodrine and atosiban inhibited integral activity to a greater extent than expected [e.g. using EC50: observed inhibition 88.9% (13.8%) vs expected inhibition 75%; P < 0.015]. Actual inhibition by nicardipine/ritodrine [78.55% (20.4%) vs 75%; P = n.s.] and nicardipine/atosiban [78.94% (17.8%) vs 75%; P = n.s.] was not significantly different from expected. Conclusions: A combination of ritodrine plus atosiban exhibits a synergistic inhibition for myometrial activity, thus allowing the use of lower concentrations of each drug to achieve the same effect compared with each drug used alone. Combination of nicardipine plus ritodrine and nicardipine plus atosiban achieves only an additive effect. The potential for decreasing side effects (beta-mimetics) and costs (atosiban) when using a combination in clinical practice needs to be evaluated.

UR - http://www.scopus.com/inward/record.url?scp=0042199026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042199026&partnerID=8YFLogxK

U2 - 10.1111/j.1471-0528.2003.02443.x

DO - 10.1111/j.1471-0528.2003.02443.x

M3 - Article

VL - 110

SP - 731

EP - 734

JO - BJOG: An International Journal of Obstetrics and Gynaecology

JF - BJOG: An International Journal of Obstetrics and Gynaecology

SN - 1470-0328

IS - 8

ER -